Overview

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced

Status:
Recruiting

Trial end date:
2025-03-02

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of FCN-437c in combination with letrozole or anastrozole ± Goserelin versus placebo combined with letrozole or anastrozole ± Goserelin in women with first-line advanced breast cancer in HR+ and HER2-.

Phase:

Phase 3

Details

Lead Sponsor:

Ahon Pharmaceutical Co., Ltd.

Treatments:

Anastrozole
Goserelin
Letrozole